MAPS’ clinical research team has completed creating a master drug tracking system for all MAPS’ MDMA studies. This database keeps records about manufacturing, shipping, quality control, and analysis of the drugs over years. We now have a central method of drug accountability to review at the conclusion of a MDMA trial, which gives a comprehensive assessment of what happened to the MDMA from start to finish. Our records go back to 2003 when the first MDMA was shipped for our pilot study in Charleston, S.C.